Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
$0.04
-4.5%		$0.08
$0.03
▼
$8.60
$1.21M0.6413.36 million shs286,611 shs
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
$0.04
-4.5%		$0.08
$0.03
▼
$8.60
$1.21M0.6413.36 million shs286,611 shs
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
$0.89
-2.9%		$1.15
$0.55
▼
$3.83
$81.98M1.751.03 million shs403,630 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
-4.55%-42.62%-49.94%-53.33%-99.18%
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
-4.55%-42.62%-49.94%-53.33%-99.18%
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-2.88%-3.25%-21.27%-30.50%+42.98%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
$0.04
-4.5%		$0.08
$0.03
▼
$8.60
$1.21M0.6413.36 million shs286,611 shs
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
$0.04
-4.5%		$0.08
$0.03
▼
$8.60
$1.21M0.6413.36 million shs286,611 shs
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
$0.89
-2.9%		$1.15
$0.55
▼
$3.83
$81.98M1.751.03 million shs403,630 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
-4.55%-42.62%-49.94%-53.33%-99.18%
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
-4.55%-42.62%-49.94%-53.33%-99.18%
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-2.88%-3.25%-21.27%-30.50%+42.98%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
2.00
Hold$3.007,042.86% Upside
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
2.00
Hold$3.007,042.86% Upside
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
2.50
Moderate Buy$3.33274.70% Upside

Current Analyst Ratings Breakdown

Latest CGTX, ASNS, and ASNS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2026
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
6/22/2026
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$3.00
(Data available from 8/1/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
$3.67M0.33N/AN/A$0.60 per share0.07
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
$3.67M0.33N/AN/A$0.60 per share0.07
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/AN/AN/AN/A$0.39 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
-$8.26M-$3.96N/AN/AN/A-225.03%-290.78%-111.82%8/13/2026 (Estimated)
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
-$8.26M-$3.96N/AN/AN/A-225.03%-290.78%-111.82%8/13/2026 (Estimated)
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-$23.49M-$0.24N/AN/AN/AN/A-72.68%-53.07%8/6/2026 (Estimated)

Latest CGTX, ASNS, and ASNS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2026Q2 2026
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
-$0.10N/AN/AN/A$1.20 millionN/A
8/13/2026Q2 2026
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
-$0.10N/AN/AN/A$1.20 millionN/A
8/6/2026Q2 2026
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-$0.06N/AN/AN/A$5.00 millionN/A
5/7/2026Q1 2026
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
-$0.06-$0.05+$0.01-$0.05$4.40 millionN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
N/AN/AN/AN/AN/A
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
N/AN/AN/AN/AN/A
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
0.03
2.46
1.76
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
0.03
2.46
1.76
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
N/A
5.92
5.92

Institutional Ownership

CompanyInstitutional Ownership
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
12.43%
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
12.43%
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
43.35%

Insider Ownership

CompanyInsider Ownership
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
0.19%
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
0.19%
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
11.11%
CompanyEmployeesShares OutstandingFree FloatOptionable
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
4028.84 million26.66 millionN/A
Actelis Networks, Inc. stock logo
ASNS
Actelis Networks
4028.84 million26.66 millionN/A
Cognition Therapeutics, Inc. stock logo
CGTX
Cognition Therapeutics
2089.50 million79.56 millionNot Optionable

Recent News About These Companies

Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
July 30 at 10:28 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/cognition-therapeutics-inc-nasdaqcgtx-receives-consensus-recommendation-of-moderate-buy-from-analysts-2026-07-30/
Cognition Therapeutics (CGTX) to Post Quarterly Earnings on Thursday
July 30 at 6:25 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/cognition-therapeutics-cgtx-to-post-quarterly-earnings-on-thursday-2026-07-30/
Cognition Therapeutics (NASDAQ:CGTX) Trading Up 3.3% - Time to Buy?
July 27, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/cognition-therapeutics-nasdaqcgtx-trading-up-33-time-to-buy-2026-07-27/
Cognition Therapeutics CEO Lisa Ricciardi to Participate in B. Riley Mind, Muscle & Vision Summit Fireside Discussion
July 13, 2026  |  quiverquant.comQ
Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit
July 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/13/3326105/0/en/cognition-therapeutics-participating-in-fireside-chat-at-b-riley-securities-mind-muscle-vision-summit.html
Cognition Therapeutics: Clearer FDA Path, But Potential Dilution Risks Remain
June 27, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4918029-cognition-therapeutics-clearer-fda-path-but-potential-dilution-risks-remain
Cognition Therapeutics gets positive FDA feedback over phase 3 study of DLB psychosis – but CGTX stock just crashed 33%
June 24, 2026  |  msn.comhttps://www.msn.com/en-in/science/general/cognition-therapeutics-gets-positive-fda-feedback-over-phase-3-study-of-dlb-psychosis-but-cgtx-stock-just-crashed-33/ar-AA26sts4
Cognition Therapeutics advances after FDA supports key elements of pivotal trial plan (CGTX)
June 24, 2026  |  msn.comhttps://www.msn.com/en-us/money/general/cognition-therapeutics-advances-after-fda-supports-key-elements-of-pivotal-trial-plan-cgtx/ar-AA26rgQo
Cognition Therapeutics Secures FDA Alignment for Phase 3 Zervimesine Trial in DLB Psychosis
June 24, 2026  |  quiverquant.comQ
Cognition Therapeutics Aligns on Key Aspects of Pivotal Study for Zervimesine (CT1812) in DLB Psychosis Following Receipt of FDA Meeting Minutes
June 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/24/3316738/0/en/cognition-therapeutics-aligns-on-key-aspects-of-pivotal-study-for-zervimesine-ct1812-in-dlb-psychosis-following-receipt-of-fda-meeting-minutes.html
Cognition Therapeutics Shareholders Elect Directors, Ratify Auditor
June 18, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/cognition-therapeutics-shareholders-elect-directors-ratify-auditor?utm_source=marketbeat.com&utm_medium=referral
Cognition Therapeutics Receives Notice of Allowance for Zervimesine Patent Application from USPTO
June 16, 2026  |  quiverquant.comQ
Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045
June 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/16/3312453/0/en/cognition-therapeutics-announces-new-composition-of-matter-patent-extending-patent-protection-for-lead-candidate-zervimesine-ct1812-through-2045.html
Cognition Therapeutics (CGTX) Gets a Buy from H.C. Wainwright
June 9, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/2384070/cognition-therapeutics-cgtx-gets-a-buy-from-h-c-wainwright/
Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies?
June 3, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/sectors/healthcare/articles/cognition-therapeutics-inc-cgtx-moving-135629346.html
Is Cognition Therapeutics, Inc. (CGTX) Moving Closer to a Registrational Trial in Dementia With Lewy Bodies?
June 2, 2026  |  insidermonkey.comhttps://www.insidermonkey.com/blog/is-cognition-therapeutics-inc-cgtx-moving-closer-to-a-registrational-trial-in-dementia-with-lewy-bodies-1773527/
Cognition Therapeutics, Inc. CEO Lisa Ricciardi to Present at June Financial Conferences on DLB Psychosis Registration Program
June 1, 2026  |  quiverquant.comQ
Cognition Therapeutics Participating in Upcoming Investor Conferences
June 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/01/3304237/0/en/cognition-therapeutics-participating-in-upcoming-investor-conferences.html
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with ...
May 21, 2026  |  caledonianrecord.comC
Cognition Therapeutics, Inc. Reports Positive FDA Meeting on Zervimesine Development for Dementia with Lewy Bodies Psychosis
May 21, 2026  |  quiverquant.comQ
Cognition Therapeutics Completes Meeting with FDA for Zervimesine (CT1812) in Dementia with Lewy Bodies with Psychosis
May 21, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/21/3299218/0/en/cognition-therapeutics-completes-meeting-with-fda-for-zervimesine-ct1812-in-dementia-with-lewy-bodies-with-psychosis.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Actelis Networks stock logo

Actelis Networks NASDAQ:ASNS

$0.04 0.00 (-4.55%)
As of 07/31/2026 03:56 PM Eastern

Actelis Networks, Inc. engages in the design, development, manufacture, and marketing of cyber hardened, hybrid fiber, networking solutions for Internet of Things and telecommunication companies in North America, Europe, the Middle East, Israel, and the Asia Pacific. It provides rapid-deployment networking solutions for wide-area IoT applications, including federal, state, and local governments; intelligent traffic systems; and military, utility, rail, telecom, and campus applications. The company's products include ethernet access devices; network aggregator switches; and Advanced MetaLIGHT/ Gigaline element management systems software, which enables remote management, monitoring, maintenance, and configuration of the installed equipment in the network. It also offers dynamic spectral software; and access broadband equipment. It serves offers its products through system integrators, distributors, contractors, resellers, and consultants. The company was incorporated in 1998 and is headquartered in Fremont, California.

Actelis Networks stock logo

Actelis Networks NASDAQ:ASNS

$0.04 0.00 (-4.55%)
As of 07/31/2026 03:56 PM Eastern

Actelis Networks, Inc. engages in the design, development, manufacture, and marketing of cyber hardened, hybrid fiber, networking solutions for Internet of Things and telecommunication companies in North America, Europe, the Middle East, Israel, and the Asia Pacific. It provides rapid-deployment networking solutions for wide-area IoT applications, including federal, state, and local governments; intelligent traffic systems; and military, utility, rail, telecom, and campus applications. The company's products include ethernet access devices; network aggregator switches; and Advanced MetaLIGHT/ Gigaline element management systems software, which enables remote management, monitoring, maintenance, and configuration of the installed equipment in the network. It also offers dynamic spectral software; and access broadband equipment. It serves offers its products through system integrators, distributors, contractors, resellers, and consultants. The company was incorporated in 1998 and is headquartered in Fremont, California.

Cognition Therapeutics stock logo

Cognition Therapeutics NASDAQ:CGTX

$0.89 -0.03 (-2.88%)
Closing price 07/31/2026 04:00 PM Eastern
Extended Trading
$0.91 +0.02 (+2.18%)
As of 07/31/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas